IOVA
Iovance Biotherapeutics Inc
$12.22
Earnings Summary
Net Profits | $-99.35Mn |
Highlights
Iovance Biotherapeutics Inc’s net profit fell -22.12% since last year same period to $-99.35Mn in the Q2 2022. On a quarterly growth basis, Iovance Biotherapeutics Inc has generated -8.45% fall in its net profits since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Iovance Biotherapeutics Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.61 |
EPS Estimate Current Year | -0.61 |
Highlights
Iovance Biotherapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.61 - a 4.69% jump from last quarter’s estimates.
Iovance Biotherapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.61.
Key Ratios
Key ratios of the Iovance Biotherapeutics Inc post its Q2 2022 earnings
Return on Assets (ROA) | -0.32 |
Return on Equity (ROE) | -0.62 |
Dividend Per Share (DPS) | 0 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Iovance Biotherapeutics Inc’s return on assets (ROA) stands at -0.32.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Iovance Biotherapeutics Inc’s return on equity (ROE) stands at -0.62.
Iovance Biotherapeutics Inc declared 0 dividend per share during the earnings announcement for Q2 2022.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-05-05 | -0.64 | -0.58 | 9.38% |
Company Information
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company's TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers.
Organisation | Iovance Biotherapeutics Inc |
Headquarters | San Carlos, California, US |
Employees | 241 |
Industry | Health Technology |
CEO | Maria Fardis |